David Woodard, MD
Clinical Cardiac Electrophysiology · Pensacola, FLNPI 1598736670
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Elutia, Inc. at 54.2% of the total. Reporting peaked in 2021 at $8,422 and has fallen 69.8% since, to $2,542 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in FL, where the typical reported total is $25,729.
Across 181 payments — averaging $88.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Elutia, Inc.$9K
- Abbott$4K
- Stryker$892
- Medtronic$671
- E.r. Squibb & Sons, L.L.C.$476
- Pfizer$179
- plus $1K from 19 others
Across 33 payments — averaging $4578.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Elutia, Inc.$125K
- Abbott$26K
What the payments were for
- Speaking & faculty fees$6,45840%
- Grants$3492%
- Travel & lodging$3,02319%
- Food & beverage$6,22639%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Elutia, Inc. | 16 | $8,696 |
| Abbott | 63 | $4,012 |
| Stryker | 10 | $892 |
| Medtronic | 9 | $671 |
| E.r. Squibb & Sons, L.L.C. | 23 | $476 |
| Pfizer | 10 | $179 |
| Impulse Dynamics (USA) Inc. | 3 | $179 |
| Edwards Lifesciences | 2 | $147 |
| Baxter Healthcare | 4 | $101 |
| Novartis | 6 | $87 |
| Sanofi-aventis U.S. LLC | 4 | $82 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $81 |
| Atricure, Inc. | 2 | $73 |
| Amgen | 5 | $73 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $53 |
| Johnson & Johnson(2 entities) | 3 | $43 |
| Alnylam Pharmaceuticals Inc. | 3 | $36 |
| Boston Scientific | 1 | $29 |
| Cardiva Medical, Inc. | 1 | $27 |
| AstraZeneca | 2 | $27 |
| Merck | 1 | $24 |
| Abiomed | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,056 in reported general payments places this provider in the 30th percentile of 249 clinical cardiac electrophysiology providers in Florida.
See all clinical cardiac electrophysiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 320 | $353,679 |
| EntrestoSacubitril/Valsartan | 92 | $97,325 |
| XareltoRivaroxaban | 66 | $71,549 |
| MultaqDronedarone Hcl | 34 | $40,258 |
| Repatha SureclickEvolocumab | 14 | $11,029 |
| Metoprolol Succinate | 275 | $3,422 |
| Ranolazine ErRanolazine | 36 | $3,168 |
| Flecainide Acetate | 36 | $2,536 |
| Atorvastatin Calcium | 176 | $2,142 |
| Nebivolol Hcl | 19 | $2,045 |
| Carvedilol | 165 | $1,729 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 83 | $1,044 |
| Potassium Chloride | 43 | $907 |
| Warfarin Sodium | 76 | $903 |
| Losartan Potassium | 129 | $860 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $179 | $353,679320 claims |
| NovartisEntresto | $87 | $97,32592 claims |
| Johnson & JohnsonXarelto | $43 | $71,54966 claims |
| Sanofi-aventis U.S. LLCMultaq | $82 | $40,25834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 249 clinical cardiac electrophysiology providers in Florida.
Other clinical cardiac electrophysiology in Pensacola
- Sumit VermaPensacola$77K
- Thabet AlsheikhPensacola$72K
- Usman SiddiquiWinter Park$1.2M
- Jose Osorio FilhoMiami$1.2M
- David KenigsbergFort Lauderdale$1M
- Raul WeissMiami Beach$887K
- Naushad ShaikKissimmee$691K
- Parikshit SharmaWeston$462K
- Saumil OzaJacksonville$462K
- Brian BetenskySarasota$412K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.